Scarica l'app Stockscreener
23.70
0.25%
-0.02
Precedente Chiudi:
$23.72
Aprire:
$23.51
Volume 24 ore:
72,359
Relative Volume:
0.14
Capitalizzazione di mercato:
$1.65B
Reddito:
$133.62M
Utile/perdita netta:
$-177.37M
Rapporto P/E:
-11.07
EPS:
-2.14
Flusso di cassa netto:
$23.50M
1 W Prestazione:
+0.68%
1M Prestazione:
+12.24%
6M Prestazione:
-0.46%
1 anno Prestazione:
+27.89%
Intervallo 1D:
$23.50
$23.86
Intervallo di 1 settimana:
$22.60
$23.86
Portata 52W:
$15.31
$26.84
Xencor Inc Stock (XNCR) Company Profile
Nome
Xencor Inc
Settore
Industria
Telefono
626-305-5900
Indirizzo
465 N. HALSTEAD ST., PASADENA, CA
Confronta XNCR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| XNCR | 23.66 | 1.65B | 133.62M | -177.37M | 23.50M | -2.14 |
| VRTX | 446.78 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.30 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 586.52 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.35 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.55 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-04-16 | Reiterato | BTIG Research | Buy |
| 2024-02-28 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | Iniziato | BofA Securities | Buy |
| 2022-12-06 | Iniziato | Cowen | Outperform |
| 2022-10-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-01-21 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-15 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-02-24 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | Iniziato | Barclays | Underweight |
| 2020-02-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-01-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-11-20 | Ripresa | Guggenheim | Neutral |
| 2019-08-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-08-07 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-04-12 | Iniziato | Guggenheim | Buy |
| 2019-03-27 | Iniziato | Berenberg | Buy |
| 2019-03-15 | Iniziato | Raymond James | Outperform |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-03-28 | Ripresa | Leerink Partners | Outperform |
| 2017-03-02 | Iniziato | Instinet | Neutral |
| 2017-03-02 | Reiterato | Wedbush | Outperform |
| 2016-10-04 | Iniziato | Piper Jaffray | Overweight |
| 2015-12-22 | Iniziato | Canaccord Genuity | Buy |
| 2015-08-05 | Reiterato | MLV & Co | Buy |
| 2015-02-12 | Reiterato | Oppenheimer | Outperform |
| 2015-01-28 | Reiterato | MLV & Co | Buy |
| 2014-07-11 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Xencor Inc Borsa (XNCR) Ultime notizie
Xencor Reports Q3 2024 Earnings and Program Updates - TipRanks
Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross - MSN
Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade - MSN
Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
(XNCR) Proactive Strategies - Stock Traders Daily
EcoR1 Capital, LLC Increases Stake in Xencor Inc - GuruFocus.com
US Bancorp DE Reduces Stock Position in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor CEO Dahiyat Bassil sells shares worth $80,841 - Investing.com
Xencor executive sells shares worth $1.6 million By Investing.com - Investing.com Australia
Xencor executive sells shares worth $1.6 million - Investing.com India
PRIMECAP Management Bolsters Stake in Xencor Inc - GuruFocus.com
Xencor's SWOT analysis: biotech stock faces pivotal year ahead - Investing.com
Xencor's SWOT analysis: biotech stock faces pivotal year ahead By Investing.com - Investing.com UK
Xencor, Inc. (NASDAQ:XNCR) Analysts Just Slashed Next Year's Revenue Estimates By 14% - Yahoo Finance UK
Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Creative Planning - Defense World
Xencor’s (XNCR) “Outperform” Rating Reiterated at BMO Capital Markets - Defense World
Xencor (NASDAQ:XNCR) Given New $28.00 Price Target at JPMorgan Chase & Co. - Defense World
Xencor (NASDAQ:XNCR) Given Outperform Rating at Wedbush - Defense World
What is Wedbush’s Forecast for Xencor FY2024 Earnings? - Defense World
Leerink Partnrs Increases Earnings Estimates for Xencor - Defense World
Leerink Partnrs Brokers Lift Earnings Estimates for Xencor - MarketBeat
What is Wedbush's Forecast for Xencor FY2024 Earnings? - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Just Reported And Analysts Have Been Cutting Their Estimates - Simply Wall St
Xencor (NASDAQ:XNCR) Receives "Outperform" Rating from BMO Capital Markets - MarketBeat
Xencor shares target raised, rating held on pipeline progress By Investing.com - Investing.com Canada
Xencor shares target raised, rating held on pipeline progress - Investing.com
Xencor (NASDAQ:XNCR) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Xencor (NASDAQ:XNCR) shareholders are up 7.9% this past week, but still in the red over the last three years - Simply Wall St
Xencor Reports Third Quarter 2024 Financial Results - BioSpace
Xencor Inc earnings beat by $0.27, revenue fell short of estimates - Investing.com Canada
Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Xencor: Q3 Earnings Snapshot - San Antonio Express-News
Trading (XNCR) With Integrated Risk Controls - Stock Traders Daily
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease - BioSpace
Please Don’t Call Me a ‘Genus’: The High Bar for Section 112 in the Unpredictable Arts as Illustrated by In re Xencor - IPWatchdog.com
942 in Development for Patients with Inflammatory Bowel Disease - Business Wire
Does Xencor (XNCR) Have the Potential to Rally 68.16% as Wall Street Analysts Expect? - Yahoo Finance
Xencor (XNCR) Expected to Beat Earnings Estimates: Should You Buy? - MSN
Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of "Buy" by Brokerages - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of “Buy” by Analysts - Defense World
Xencor Inc Azioni (XNCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.42%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):